Cue Biopharma (CUE) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Cue Biopharma is the larger company by market cap ($121.4 million vs $117.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | RTSN |
|---|---|---|
| Share price | $16.71 | $14.07 |
| Market cap | $121.39M | $117.23M |
| 1-day change | -10.50% | +15.23% |
| YTD return | +82.62% | — |
| 1-year return | -30.03% | — |
| 5-year return | -95.32% | — |
| EPS (TTM) | $-29.59 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.47M | — |
| Revenue growth (YoY) | +195.75% | — |
| Net income (latest FY) | $-26.60M | — |
| Operating margin | -96.67% | — |
| Net margin | -96.85% | — |
| 52-week high | $45.50 | $14.97 |
| 52-week low | $4.98 | $9.66 |
| Distance from 52-week high | -63.27% | -6.02% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +426.63% | — |
| Average volume | 272.41K | 252.97K |
| Shares outstanding | 7.26M | 8.33M |
| Employees | 29 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
CUE vs RTSN FAQ
Which is bigger, Cue Biopharma or Retension Pharmaceuticals?
Cue Biopharma (CUE) is larger, with a market capitalization of $121.39M compared with $117.23M for Retension Pharmaceuticals (RTSN).
Are Cue Biopharma and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.